Soft Tissue Sarcoma Competitive Landscape Analysis 2024: 361 Molecules in the Pipeline, Including 10 Drugs in the Late-stage Pipeline with Roche, BMS, Novartis, and Boehringer Ingelheim Leading
31 juil. 2024 10h50 HE
|
Research and Markets
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Soft Tissue Sarcoma: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report provides a data-driven...
Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati
03 août 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme,...
Europe Soft Tissue Sarcoma Market Report 2023: Growing Focus on Personalized Medicine Presents Opportunities
31 mai 2023 05h38 HE
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type, By End...
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
22 sept. 2021 09h00 HE
|
Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...